Scientific REPOrts | (2018) 8:15109 | DOI:10.1038/s41598-018-30974-w 1
www.nature.com/scientificreports
Author Correction: A Donor Quality 
Index for liver transplantation: 
development, internal and external 
validation
AudreyWinter 1,2,3, Cyrille Féray4, EtienneAudureau5, DanielAzoulay6, CorinneAntoine7, 
Jean-Pierre Daurès1,2 & Paul Landais1
Correction to: Scientific Reports https://doi.org/10.1038/s41598-018-27960-7, published online 29 June 2018
This Article contains errors.
In Table 1, the formatting for the header “Recipient characteristics” is incorrect. The correct Table 1 appears 
below:
1Department of Biostatistics, UPRES EA2415, Clinical Research University Institute, Montpellier, France. 2Beau 
Soleil Clinic, Montpellier, France. 3
Department of Radiological Sciences, University of California, Los Angeles, CA, 
USA. 4Department of Hepatology, Henri Mondor Hospital, Créteil, France. 5Department of Public Health, Henri 
Mondor Hospital, Créteil, France. 6
Department of Surgery, Henri Mondor Hospital, Créteil, France. 7
Agence de la 
Biomédecine, Saint-Denis, France. Correspondence and requests for materials should be addressed to A.W. (email: 
audrey.winter89@gmail.com)
Published: xx xx xxxx
OPEN

www.nature.com/scientificreports/
Scientific REPOrts | (2018) 8:15109 | DOI:10.1038/s41598-018-30974-w 2
Donor characteristics Mean survival (sd) P-value
Sex (%): 0.37
   Male 55.01 4.55 (0.05)
   Female 44.99 4.56 (0.08)
Cause of death (%): <0.01
   Cerebrovascular accident 60.29 4.44 (0.05)
   Trauma 24.64 4.69 (0.07)
   Anoxia 12.02 4.80 (0.11)
   Other 3.05 4.72 (0.21)
Diabetes (%): 0.98
   yes 7.75 4.56 (0.14)
   no 92.25 4.56 (0.04)
ABO group (%): 0.22
   A 44.58 4.57 (0.06)
   B 9.87 4.72 (0.12)
   O 41.93 4.49 (0.06)
   AB 3.61 4.78 (0.19)
Hypertension (%): 0.21
   yes 35.70 4.49 (0.07)
   no 64.30 4.60 (0.05)
Malignancy (%): 0.43
   yes 1.89 4.72 (0.26)
   no 98.11 4.49 (0.04)
Alcohol (%): 0.53
   yes 15.02 4.50 (0.10)
   no 84.98 4.57 (0.04)
Smoking (%): 0.47
   yes 37.59 4.59 (0.06)
   no 62.41 4.53 (0.05)
Drugs (%): 0.52
   yes 4.17 4.65 (0.19)
   no 95.83 4.56 (0.04)
Hepatitis C virus antibody (%): 0.46
   + 0.45 4.09 (0.56)
   − 99.55 4.53 (0.04)
Hepatitis B core antibody (%): 0.62
   + 4.39 4.61 (0.18)
   − 95.61 4.53 (0.04)
Inotropes (dobutamine, dopamine, noradrenaline, epinephrine) (%): 0.72
   yes 39.16 4.57 (0.06)
   no 60.84 4.55 (0.05)
Liver type (%): 0.44
   Partial/split 5.10 4.43 (0.17)
   Total 94.90 4.55 (0.04)
Age (%): <0.001
   ≤69 76.47 4.64 (0.04)
   >69 23.53 4.27 (0.09)
Height (%): 0.07
   <162 22.62 4.42 (0.08)
   ≥162 77.38 4.60 (0.04)
Weight, mean (sd) 72.88 (15.17)
BMI, mean (sd) 25.33 (4.62)
Sodium: latest (mmol/L) (%): 0.04
   136–146 43.85 4.47(0.06)
   other 56.15 4.63(0.05)
Sodium: highest (mmol/L), median (range) 149 (120-180)
MDRD creatinine clearance: latest (ml/min/1.73m2
) (%): 0.01
   <60 25.30 4.38 50.08)
Continued

www.nature.com/scientificreports/
Scientific REPOrts | (2018) 8:15109 | DOI:10.1038/s41598-018-30974-w 3
Donor characteristics Mean survival (sd) P-value
   60–89 29.51 4.55 (0.07)
   ≥90 45.19 4.66 (0.06)
MDRD creatinine clearance: lowest (ml/min/1.73m2
) (%): 0.01
   <60 35.35 4.41 (0.07)
   60–89 36.83 4.61 (0.06)
   ≥90 27.82 4.68 (0.07)
Aspartate aminotransferase: latest (U/L), median (range) 39 (0–2000)
Aspartate aminotransferase: highest (U/L), median (range) 51 (9–2000)
Alanine transaminase: latest (U/L) (%): 0.04
   7–41 67.33 4.50 (0.05)
   other 32.67 4.67 (0.07)
Alanine transaminase: highest (U/L), median (range) 33 (1–2000)
Total bilirubin: latest (µmol/L), median (range) 10 (0–150)
Total bilirubin: highest (µmol/L), median (range) 12 (1–150)
Alkaline phosphatases: latest (U/L) (%): 0.06
   <33 4.44 4.26 (0.19)
   33–96 76.12 4.54 (0.04)
   >96 19.44 4.71 (0.08)
Alkaline phosphatases: highest (U/L) (%): 0.09
   <33 1.78 4.22 (0.31)
   33–96 72.22 4.51 (0.05)
   >96 26.00 4.67 (0.07)
Gamma glutamyl transpeptidase: latest (U/L), median (range) 30 (0–1477)
Gamma glutamyl transpeptidase: highest (U/L), median (range) 36 (1–1835)
Intensive care unit stay (in days) (%): <0.001
   ≤4 79.68 4.48 (0.04)
   >4 29.32 4.83 (0.08)
Estimated distance between donor and recipient location (minutes) (%): <0.01
   <15 22.60 4.77 (0.08)
   ≥15 77.40 4.50 (0.04)
“Hors tour” (%): 0.84
   yes 6.08 4.57 (0.16)
   no 93.92 4.55 (0.04)
Donor risk index, mean (sd) 1.65 (0.40) — —
Eurotransplant donor risk index, mean (sd) 1.63 (0.36) — —
UK Donor Liver Index, mean (sd) 1.15 (0.26) — —
Recipient characteristics Mean survival (sd) P-value
Sex (%): 0.91
   Male 73.54 4.55 (0.05)
   Female 26.46 4.56 (0.08)
Cancer (%): 0.29
   yes 29.00 4.62 (0.07)
   no 71.00 4.53 (0.05)
Decompensated cirrhosis (%): <0.001
   yes 37.74 4.73 (0.06)
   no 62.26 4.46 (0.05)
Non-cirrhotic liver disease (%): 0.63
   yes 1.41 4.63 (0.30)
   no 98.59 4.48 (0.04)
Emergency (%): <0.001
   yes 6.72 3.78 (0.17)
   no 93.28 4.58 (0.04)
MELD exception (%): 0.36
   yes 18.00 4.45 (0.09)
   no 82.00 4.57 (0.04)
Previous transplantation (%): <0.001
   yes 8.58 3.76 (0.15)
Continued

www.nature.com/scientificreports/
Scientific REPOrts | (2018) 8:15109 | DOI:10.1038/s41598-018-30974-w 4
In addition, Table 2 contains formatting errors. The correct Table 2 appears below:
Recipient characteristics Mean survival (sd) P-value
   no 91.42 4.60 (0.04)
On dialysis (%): <0.001
   yes 5.33 3.43 (0.19)
   no 94.67 4.58 (0.04)
Medical condition before LT (%): <0.001
Intensive care unit 17.70 3.88 (0.11)
Hospital (no intensive care unit) 13.88 4.60 (0.10)
Not hospitalized 68.42 4.71 (0.04)
Hepatitis B core antibody (%): 0.73
   + 20.05 4.53 (0.09)
   − 79.95 4.56 (0.04)
Hepatitis C virus antibody (%): <0.001
   + 23.83 4.23 (0.08)
   − 76.17 4.66 (0.04)
Diabetes (%): 0.06
   yes 22.67 4.42 (0.08)
   no 77.33 4.60 (0.04)
Encephalopathy (%): <0.001
   grade 1 68.14 4.62 (0.05)
   grade 2 24.84 4.52 (0.08)
   grade 3 7.02 3.95 (0.17)
ABO group (%): 0.80
   A 45.44 4.56 (0.06)
   B 11.16 4.63 (0.11)
   O 39.03 4.55 (0.06)
   AB 4.37 4.43 (0.19)
Age, mean (sd) 53.24 (10.39)
Body mass index (%): 0.20
   <18.5 3.56 4.35 (0.21)
   18.5–25 44.69 4.50 (0.06)
   ≥25 51.75 4.62 (0.05)
Model for end stage liver disease before LT (%): <0.001
   <29 72.73 4.65 (0.04)
   ≥29 27.27 4.32 (0.08)
Waiting time (in days) (%): <0.001
   <21 24.54 4.34 (0.08)
   ≥21 75.46 4.63 (0.04)
Follow-up (years), mean (sd) 2.33 (1.63)
Table 1. Donor and recipient characteristics with Log-rank test p-value for qualitative variables and 
quantitative variables across risk groups when significant threshold was met.

www.nature.com/scientificreports/
Scientific REPOrts | (2018) 8:15109 | DOI:10.1038/s41598-018-30974-w 5
Finally, there are errors in Table 5, where the formatting of the “Donor characteristics” header is incorrect. 
Additionally, the word “Hospital” is incorrectly given as “Hosptial” and the P-values for “ICU stay (in days)” and 
“Clearance MDRD: lowest (ml/min/1.73m2)” are omitted. The correct Table 5 appears below as Table 3:
Covariates Model 1 Model 2 Model 3 Final model
Donor
Age × × × ×
Cause of death × × × ×
Intensive care unit stay × × × ×
ABO group × × (adjustment)
MDRD creatinine clearance: lowest × ×
Partial/split liver × ×
Alcohol ×
Alkanine phosphatases: latest ×
Estimated distance ×
Recipient
Re-transplantation × × × ×
On dialysis × × × ×
Medical condition before LT × × × ×
Hepatitis C virus antibody × × × ×
Diabetes × × × ×
Decompensated cirrhosis × × × ×
MELD exception × ×
ABO group × ×
Perfomances
C-index 0.626(0.009) 0.616(0.009) 0.616(0.009) 0.625(0.009)
K statistic 0.617(0.007) 0.611(0.008) 0.610(0.008) 0.616(0.007)
RD
2 0.518(0.020) 0.492(0.021) 0.492(0.021) 0.516(0.021)
Table 2. Retained covariates in the different selection way. Covariates in bold are those which appeared in the 
three selection models. Model 1: A complete model with selection according to the Akaiké criterion; Model 
2: (1) log rank tests with a threshold of 20%, (2) multivariate model included the selected covariates with a 
selection threshold set at 20%; Model 3: (1) log rank tests with a threshold of 20%, (2) two multivariate models 
for donor and recipient with the selected covariates with a selection threshold set at 20%, (3) multivariate model 
with all the covariates selected with a selection threshold set at 20%. The retained full model included all the 
variables present in at least two of the three models and the set of covariates retained in addition.

www.nature.com/scientificreports/
Scientific REPOrts | (2018) 8:15109 | DOI:10.1038/s41598-018-30974-w 6
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre￾ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per￾mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
© The Author(s) 2018
Recipient characteristics 2009–2013 (n = 3961) 2014 (n = 1048) P- values
Expert component (no) 3248 (82%) 874 (83.4%) 0.31
ABO group 0.59
   A 1800 (45.44%) 465 (44.37%)
   AB 173 (4.37%) 38 (3.63%)
   B 442 (11.16%) 118 (11.26%)
   O 1546 (39.03%) 427 (40.74%)
Re-transplantation (no) 3621 (91.42%) 961 (91.7%) 0.82
On dialysis (no) 3750 (94.67%) 987 (94.18%) 0.58
Medical condition before LT 0.45
   Home 2710 (68.42%) 705 (67.27%)
   Hospital 550 (13.89%) 140 (13.36%)
   ICU 701 (17.7%) 203 (19.37%)
Hepatitis C virus antibody (−) 3017 (76.17%) 811 (77.39%) 0.43
Diabetes (no) 3063 (77.33%) 793 (75.67%) 0.27
Decompensated cirrhosis (no) 2466 (62.26%) 667 (63.65%) 0.43
Donor characteristics 2009–2013 (n = 3961) 2014 (n = 1048) P-values
ABO group 0.75
   A 1766 (44.58%) 460 (43.89%)
   AB 143 (3.61%) 32 (3.05%)
   B 391 (9.87%) 102 (9.73%)
   O 1661 (41.93%) 454 (43.32%)
Age <0.01
   ≤69 3029 (76.47%) 710 (67.75%)
   >69 932 (23.53%) 338 (32.25%)
COD <0.01
   Anoxia 476 (12.02%) 150 (14.31%)
   CVA 2388 (60.29%) 651 (62.12%)
   Trauma 976 (24.64%) 231 (22.04%)
   Other 121 (3.05%) 16 (1.53%)
ICU stay (in days) 0.23
   ≤4 3156 (79.68%) 853 (81.39%)
   >4 805 (20.32%) 195 (18.61%)
Clearance MDRD: lowest (ml/
min/1.73 m2
) 0.55
   <60 1400 (35.34%) 385 (36.74%)
   60–89 1459 (36.83%) 388 (37.02%)
   ≥90 1102 (27.82%) 275 (26.24%)
Liver type (entire) 3759 (94.9%) 1007 (96.09%) 0.13
Table 3. Differences in donor and recipient characteristics between the derivation and validation datasets 
(P-values, χ2
 tests and ANOVA when appropriate).

